Search

Displaying results 2541 - 2550 of 4236 in total
  1. Drug

    Arsenic trioxide

    go.drugbank.com/drugs/DB01169
    ApprovedInvestigational

    The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

  2. Drug

    Xanthan gum

    go.drugbank.com/drugs/DB11253
    Approved

    It is used as a thickening agent and stabilizer in emulsions.

  3. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin.

  4. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    Raxtozinameran is also known as Pfizer-BioNTech COVID-19 Vaccine and Comirnaty.

  5. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.

  6. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.

  7. Drug

    Sodium aurothiomalate

    go.drugbank.com/drugs/DB09276
    ApprovedWithdrawn

    Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL.

  8. Drug

    Zofin

    go.drugbank.com/drugs/DB16519
    Investigational

    Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the

  9. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  10. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment. … [L63806,L63934] Established ADHD pharmacotherapy acts on norepinephrine and dopamine without a serotonergic component, and Otsuka describes centanafadine as the first and only approved norepinephrine-dopamine-serotonin